-
Je něco špatně v tomto záznamu ?
Therapeutic monitoring of carbamazepine and its active metabolite during the 1st postnatal month: Influence of drug interactions
I. Kacirova, M. Grundmann, H. Brozmanova
Jazyk angličtina Země Francie
Typ dokumentu časopisecké články
- MeSH
- antikonvulziva metabolismus farmakokinetika MeSH
- biotransformace MeSH
- dospělí MeSH
- enzymová indukce účinky léků MeSH
- epoxidové sloučeniny metabolismus MeSH
- karbamazepin metabolismus farmakokinetika MeSH
- kohortové studie MeSH
- kojení MeSH
- kyselina valproová farmakokinetika MeSH
- lékové interakce MeSH
- lidé MeSH
- mateřské mléko chemie metabolismus MeSH
- mladý dospělý MeSH
- monitorování léčiv MeSH
- novorozenec MeSH
- Check Tag
- dospělí MeSH
- lidé MeSH
- mladý dospělý MeSH
- mužské pohlaví MeSH
- novorozenec MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
OBJECTIVE: To receive information about carbamazepine and its active metabolite 10,11-epoxide transport into mature milk and suckling infants. METHODS: In this cohort study, maternal serum, mature milk, and infant serum carbamazepine and epoxide levels were measured between the 6th and 29th postnatal day (carbamazepine in 1990-2017, epoxide in 1997-2017). Paired maternal serum, infant serum and milk levels were used for the assessment of ratios of this levels. The influence of combined treatment with enzyme-inducing antiepileptic drugs and valproic acid was assessed. Relationship between maternal serum, infant serum, and milk levels was also evaluated. RESULTS: Maternal carbamazepine levels were 1.4-10.4 mg/L, milk 0.5-6.7 mg/L and infant 0.5-2.6 mg/L. Maternal 10,11-epoxide levels were 0.3-5.4 mg/L, milk 0.3-3.7 mg/L and infant 0.3-0.6 mg/L. Highly significant correlations were observed exclusively between milk and maternal serum levels of both carbamazepine and 10,11-epoxide. Concomitant administration of enzyme-inducing antiepileptic drugs significantly increased the maternal apparent oral clearance of carbamazepine by approximately 130%. Carbamazepine combined with valproic acid significantly increased epoxide levels in milk and maternal serum but not in breastfed infants. CONCLUSIONS: In breastfed infants, carbamazepine levels did not reach the lower limit of the therapeutic range used for the general epileptic population, and the majority of epoxide levels were less than the lower limit of quantification. Routine monitoring of carbamazepine in these infants is not compulsory. However, observation of breastfed infants is desirable. If signs of potential adverse reactions are evident, infant serum concentrations should be monitor.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21025764
- 003
- CZ-PrNML
- 005
- 20211026133533.0
- 007
- ta
- 008
- 211013s2021 fr f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.biopha.2021.111412 $2 doi
- 035 __
- $a (PubMed)33761618
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a fr
- 100 1_
- $a Kacirova, Ivana $u Department of Clinical Pharmacology, Faculty of Medicine, University of Ostrava, Syllabova 19, 703 00 Ostrava, Czech Republic; Department of Clinical Pharmacology, Department of Laboratory Medicine, University Hospital Ostrava, 17. listopadu 1790, 700 30 Ostrava, Czech Republic
- 245 10
- $a Therapeutic monitoring of carbamazepine and its active metabolite during the 1st postnatal month: Influence of drug interactions / $c I. Kacirova, M. Grundmann, H. Brozmanova
- 520 9_
- $a OBJECTIVE: To receive information about carbamazepine and its active metabolite 10,11-epoxide transport into mature milk and suckling infants. METHODS: In this cohort study, maternal serum, mature milk, and infant serum carbamazepine and epoxide levels were measured between the 6th and 29th postnatal day (carbamazepine in 1990-2017, epoxide in 1997-2017). Paired maternal serum, infant serum and milk levels were used for the assessment of ratios of this levels. The influence of combined treatment with enzyme-inducing antiepileptic drugs and valproic acid was assessed. Relationship between maternal serum, infant serum, and milk levels was also evaluated. RESULTS: Maternal carbamazepine levels were 1.4-10.4 mg/L, milk 0.5-6.7 mg/L and infant 0.5-2.6 mg/L. Maternal 10,11-epoxide levels were 0.3-5.4 mg/L, milk 0.3-3.7 mg/L and infant 0.3-0.6 mg/L. Highly significant correlations were observed exclusively between milk and maternal serum levels of both carbamazepine and 10,11-epoxide. Concomitant administration of enzyme-inducing antiepileptic drugs significantly increased the maternal apparent oral clearance of carbamazepine by approximately 130%. Carbamazepine combined with valproic acid significantly increased epoxide levels in milk and maternal serum but not in breastfed infants. CONCLUSIONS: In breastfed infants, carbamazepine levels did not reach the lower limit of the therapeutic range used for the general epileptic population, and the majority of epoxide levels were less than the lower limit of quantification. Routine monitoring of carbamazepine in these infants is not compulsory. However, observation of breastfed infants is desirable. If signs of potential adverse reactions are evident, infant serum concentrations should be monitor.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a antikonvulziva $x metabolismus $x farmakokinetika $7 D000927
- 650 _2
- $a biotransformace $7 D001711
- 650 _2
- $a kojení $7 D001942
- 650 _2
- $a karbamazepin $x metabolismus $x farmakokinetika $7 D002220
- 650 _2
- $a kohortové studie $7 D015331
- 650 _2
- $a lékové interakce $7 D004347
- 650 _2
- $a monitorování léčiv $7 D016903
- 650 _2
- $a enzymová indukce $x účinky léků $7 D004790
- 650 _2
- $a epoxidové sloučeniny $x metabolismus $7 D004852
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a novorozenec $7 D007231
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a mateřské mléko $x chemie $x metabolismus $7 D008895
- 650 _2
- $a kyselina valproová $x farmakokinetika $7 D014635
- 650 _2
- $a mladý dospělý $7 D055815
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Grundmann, Milan $u Department of Clinical Pharmacology, Faculty of Medicine, University of Ostrava, Syllabova 19, 703 00 Ostrava, Czech Republic. Electronic address: milan.grundmann@osu.cz
- 700 1_
- $a Brozmanova, Hana $u Department of Clinical Pharmacology, Faculty of Medicine, University of Ostrava, Syllabova 19, 703 00 Ostrava, Czech Republic; Department of Clinical Pharmacology, Department of Laboratory Medicine, University Hospital Ostrava, 17. listopadu 1790, 700 30 Ostrava, Czech Republic
- 773 0_
- $w MED00005486 $t Biomedicine & pharmacotherapy Biomedecine & pharmacotherapie $x 1950-6007 $g Roč. 137, č. - (2021), s. 111412
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/33761618 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20211013 $b ABA008
- 991 __
- $a 20211026133539 $b ABA008
- 999 __
- $a ok $b bmc $g 1714687 $s 1146271
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 137 $c - $d 111412 $e 20210224 $i 1950-6007 $m Biomedicine & pharmacotherapy $n Biomed Pharmacother $x MED00005486
- LZP __
- $a Pubmed-20211013